
Jennifer Arnold, COO of Transit Scientific, promoted to President & CEO
April 4, 2024
Transit Scientific is excited to announce that Jennifer Arnold, current COO of Transit Scientific has been promoted to President & CEO of Transit Scientific effective immediately.
Jennifer has been with Transit Scientific for 5+ years, serving in various roles including Vice President of Engineering and Chief Operating Officer. She brings a wealth of knowledge to the role with experience in engineering, regulatory, and supply chain. Jennifer has overseen 7 FDA and 2 CE Mark submissions covering 130+ unique device SKUs with a 100% approval rate to date, currently has 1 patent allowed and 6 patents pending, and was awarded Utah Business’s 40 under 40 business leaders in 2024.
Jennifer comments, “As I transition from Chief Operating Officer to President and CEO, I am deeply honored and excited to take on this new role. With inspired dedication, I look forward to steering Transit Scientific toward continued growth and innovation. Together with our talented team, we will uphold our commitment to advancing healthcare solutions and improving patient outcomes.”
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp














